<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522091</url>
  </required_header>
  <id_info>
    <org_study_id>10-002</org_study_id>
    <nct_id>NCT02522091</nct_id>
  </id_info>
  <brief_title>Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI</brief_title>
  <acronym>IMPRO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators propose in this study to evaluate prospective memory (MP) in all its complexity
      as well as the processes, cognitive and brain, the underlying. Specifically, investigators
      propose to evaluate the evolution of the MP during normal aging and Alzheimer's disease (AD)
      to identify the cognitive and brain processes underlying this development. To do this, this
      study will have to include healthy subjects, 18 to 95 years, patients with Mild Cognitive
      Impairment (MCI) and patients with probable AD. All participants will undergo a series of
      examinations, both neuropsychological and brain imaging.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measuring the amplitude of the BOLD signal (Blood Oxygen Level Dependent)</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>young healthy volunteers (18-44 years old)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>young healthy volunteers (18-44 years old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers (45-69 years old)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>healthy volunteers (45-69 years old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mild Cognitive Impairment Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's Disease patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Alzheimer's Disease patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>old healthy volunteers (70+ years old)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>old healthy volunteers (70+ years old)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>functional brain MRI</intervention_name>
    <arm_group_label>young healthy volunteers (18-44 years old)</arm_group_label>
    <arm_group_label>healthy volunteers (45-69 years old)</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment Patients</arm_group_label>
    <arm_group_label>Alzheimer's Disease patient</arm_group_label>
    <arm_group_label>old healthy volunteers (70+ years old)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuropsychology tests</intervention_name>
    <arm_group_label>young healthy volunteers (18-44 years old)</arm_group_label>
    <arm_group_label>healthy volunteers (45-69 years old)</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment Patients</arm_group_label>
    <arm_group_label>Alzheimer's Disease patient</arm_group_label>
    <arm_group_label>old healthy volunteers (70+ years old)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants:

               -  Normal Education&gt; 7 years

               -  French mother tongue

               -  right-handed (Edinburgh Inventory)

               -  score on the scale of Beck &lt;7 (depression scale)

               -  signing the informed consent of the protocol in agreement with the Committee to
                  Protect People

               -  Medical examinations, neurological, neuropsychological and neuroimaging depth in
                  accordance with the specific inclusion and exclusion criteria for each
                  population, that is to say:

          -  Young healthy subjects aged between 18 and 44 years

          -  Healthy subjects intermediate age: between 45 and 69 years

               -  score on the Mattis Dementia Scale higher than 137, in order to exclude any
                  potential dementia

               -  Performance &quot;normal&quot; to test RI RL-16 (that is to say, not differing by more than
                  1.65 standard deviation from the norm for age and cultural level [see normative
                  values published Van der Linden et al., 2004]), test conventionally used to
                  assess the verbal episodic memory.

          -  Healthy elderly subjects aged 70 and over, living at home

               -  score on the Mattis Dementia Scale higher than 137, in order to exclude any
                  potential dementia

               -  Performance &quot;normal&quot; to test RI RL-16 (that is to say, not differing by more than
                  1.65 standard deviation from the norm for age and cultural level [see normative
                  values published Van der Linden et al., 2004]), test conventionally used to
                  assess the verbal episodic memory.

          -  MCI patients: older than 50 years and recruited from memory clinics and meet the
             current criteria and recognized including amnestic MCI

               -  memory complaint

               -  targets deficits of episodic memory (lower performance of at least 1 standard
                  deviation from the norm for age and cultural level to one or more (sub) episodic
                  memory scores of diagnostic battery - cf. . Tables 1 and infra)

               -  performance in the standards for age and cultural level in all tests of
                  diagnostic battery measuring other cognitive functions as memory, including the
                  evaluation of overall cognitive ability tests.

          -  Alzheimer's patients: older than 50 years were recruited from the clinics and memory
             satisfying the standards NINCDS-ADRDA criteria for probable AD which include

               -  abnormal global cognitive functioning and deficits in two or more cognitive
                  domains identified by the diagnostic battery

               -  mild to moderate AD (MMSE ≥ 18).

        Exclusion Criteria:

          -  Cognitive disorders of sudden onset (contrary to their slow and progressive onset in
             AD), which could reflect a stroke; a modified Hachinski ischemic score ≤ 2 (Loeb &amp;
             Gandolfo, 1983); history of head trauma with loss of consciousness for more than 1
             hour, or encephalitis;

          -  Chronic neurological disease, psychiatric, endocrine, hepatic, infectious;

          -  A history of major illness (chronic lung disease, heart disorder, metabolic,
             hematologic, endocrine or immunological severe, cancer);

          -  A medication that may interfere with the mnemonic or metabolic measures
             (psychotropics, hypnotics, anxiolytics, neuroleptics, anti-Parkinson, benzodiazepines,
             anti-inflammatory drugs, antiepileptics, antihistamines, analgesics and muscle
             relaxants central, as is usual The investigating doctor deems the annoying character
             for the study of the regular intake of certain medications). Taking anticholinesterase
             treatment will also be a criterion for non-inclusion.

          -  Chronic intake of alcohol or drugs;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de neurologie</name>
      <address>
        <city>Caen, CHU</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent de la Sayette, MD, PhD</last_name>
      <phone>02.31.06.46.24</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

